iSpace China (星际荣耀航天科技集团) was founded in October 2016 in Beijing by a team of engineers drawn from the China Aerospace Science and Technology Corporation’s First Academy (CASC 航天一院) — the institutional cradle of China’s state launch-vehicle program. Co-founders Peng Xiaobo and Yao Bowen both carry this state-system pedigree, and we view the company’s origin story as a representative case of China’s first-generation commercial-space founders: state-trained propulsion and systems talent redeployed into privately capitalized ventures. We regard this lineage as a credible technical foundation, but note that the same talent pool has spawned several of iSpace’s direct competitors, which we flag as a structural competitive-intensity risk discussed later in this report.

The company’s technology roadmap has progressed in a clear sequence: early solid sounding-rocket launches (2018) → first orbital insertion (2019) → initiation of liquid-propulsion and reusability R&D (from 2019) → successful vertical takeoff-vertical landing (VTVL) reusability demonstration (2023). In public remarks, founder Peng Xiaobo has framed the company’s risk philosophy around indefinitely deferring failure rather than avoiding it outright — a framing that, in our read, is consistent with the company’s persistence on the reusable liquid-rocket path despite four prior launch failures.

Core R&D personnel reportedly carry an average of 14-plus years of launch-vehicle development experience, which we view as a structural strength given the high entry barriers of commercial spaceflight. That said, founder ownership remains concentrated in the low-30% range, and state-affiliated capital has expanded rapidly as a share of the most recent funding rounds — a governance dynamic we believe warrants continued monitoring through subsequent rounds and listing review.

iSpace’s business model is best summarized as a dual-track “solid-plus-liquid” strategy. The commercially operational Hyperbola-1 (双曲线一号) small solid-fuel vehicle generates near-term launch revenue from research institutes and enterprise customers, while the large reusable liquid oxygen/methane Hyperbola-3 (双曲线三号, SQX-3) serves as the company’s core long-term growth vehicle. We view this dual-track structure as providing a near-term cash-flow buffer relative to peers pursuing a pure-liquid strategy, though we note the buffer’s effectiveness is constrained by Hyperbola-1’s own reliability record — four successes across eight launches to date.

Across disclosed rounds from its 2018 Series A through the February 2026 Series D++, iSpace has raised a cumulative total of approximately RMB 7.6 billion (≈ USD 1.06 billion, at an approximate CNY/USD rate of 7.15) — we treat this as a floor estimate given the likelihood of undisclosed intermediate tranches. The more structurally important pattern, in our view, is the roughly three-year gap in disclosed financing between 2021 and 2023, followed by an inflection from 2024 onward in which state-affiliated capital entered in scale and both the pace and size of rounds accelerated sharply.

China’s commercial rocket market is dominated by five companies — LandSpace, Space Pioneer, CAS Space, Galactic Energy, and iSpace — collectively dubbed the “Five Little Dragons,” whose combined valuations exceed RMB 100 billion as all five race toward public-market access. We see iSpace’s competitive positioning within this group as differentiated across six dimensions.

iSpace remains a private company and does not disclose detailed revenue or profit-and-loss figures — we flag this as an explicit information gap. For context, sector peer LandSpace reported cumulative net losses exceeding RMB 3.5 billion between 2022 and H1 2025, including H1 2025 revenue of just RMB 36.43 million against a net loss of RMB 635 million. Given the comparable scale and stage of its reusable liquid-rocket program, we believe it is reasonably likely that iSpace operates under a broadly similar structural loss profile, though we stress this is an inference rather than a verified figure.

Opportunities we would flag include: ▲ Hyperbola-3’s maiden orbital flight plus sea-recovery attempt (targeted for 2026, a potential re-rating catalyst); ▲ a successful June-2026 reuse flight test that would meaningfully advance the “China’s SpaceX” narrative; ▲ a confirmed demand pipeline anchored by the ~27,000-satellite combined Guowang/Qianfan constellation program; and ▲ funding stability afforded by aggressive state-capital inflows both pre- and post-listing.

Risks we would flag include: ▲ Hyperbola-1’s low launch success rate (four of eight), which raises quality and reliability questions that could recur on Hyperbola-3’s early flights; ▲ the unproven nature of the maiden orbital-flight-plus-sea-recovery milestone, already delayed from 2025 into 2026; ▲ a listing-review timeline that trails both LandSpace and CAS Space, creating public-market-entry timing risk; ▲ a valuation that has re-rated sharply in a short window (from the low-RMB-10-billion range to RMB 23.5B), raising entry-price risk for subsequent investors; ▲ the potential for governance and strategic-autonomy shifts as state-affiliated ownership continues to expand; and ▲ intensifying capital and talent competition from LandSpace, Space Pioneer, and other peers drawn from the same state-aerospace talent pool.